预测炎症性肠病对抗肿瘤坏死因子治疗的持久反应或耐药性。
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
作者信息
Kopylov Uri, Seidman Ernest
机构信息
Division of Gastroenterology, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv, Israel.
Professor of Medicine and Pediatrics McGill University, Director, IBD Center of Excellence at McGill, Bruce Kaufman Endowed Chair in IBD at McGill, Canada Research Chair in Immune Mediated Gastrointestinal Disorders, Digestive Lab Research Institute of the McGill University Health Centre, 1650 Cedar Avenue C10.145, Montreal, QC H3G 1A4, Canada.
出版信息
Therap Adv Gastroenterol. 2016 Jul;9(4):513-26. doi: 10.1177/1756283X16638833. Epub 2016 Apr 1.
Abstract
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.
摘要
在过去15年中，肿瘤坏死因子（TNF）单克隆抗体已成为炎症性肠病（IBD）治疗手段的中流砥柱。尽管疗效显著，但原发性和继发性无反应很常见，且与不良临床结局及高昂费用相关。多种临床、遗传和免疫药理学因素可能影响对抗TNF药物的反应。在治疗的诱导期和维持期，根据预期治疗失败风险对IBD患者进行早期分层，可能有助于优化治疗，并可能实现最佳的短期和长期结局。本综述的目的是总结目前关于IBD中抗TNF药物治疗成功和失败的潜在预测因素的数据。
相似文献
1
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.预测炎症性肠病对抗肿瘤坏死因子治疗的持久反应或耐药性。
Therap Adv Gastroenterol. 2016 Jul;9(4):513-26. doi: 10.1177/1756283X16638833. Epub 2016 Apr 1.
2
Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.在炎症性肠病中诱导抗肿瘤坏死因子治疗期间的治疗药物监测：定义治疗药物窗口。
Inflamm Bowel Dis. 2017 Sep;23(9):1510-1515. doi: 10.1097/MIB.0000000000001231.
3
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.炎症性肠病中抗 TNF 药物治疗药物监测实施中的态度、认知与障碍：一项来自中东地区的调查
Therap Adv Gastroenterol. 2024 Feb 24;17:17562848241230902. doi: 10.1177/17562848241230902. eCollection 2024.
4
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review.炎症性肠病中肿瘤坏死因子拮抗剂无应答的预测因素和最佳管理：文献综述。
World J Gastroenterol. 2023 Aug 7;29(29):4481-4498. doi: 10.3748/wjg.v29.i29.4481.
5
Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.英夫利昔单抗治疗对肿瘤坏死因子拮抗剂初次无应答的克罗恩病患者的疗效。
Dig Dis Sci. 2019 Jul;64(7):1952-1958. doi: 10.1007/s10620-019-05490-0. Epub 2019 Feb 28.
6
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.炎症性肠病中使用肿瘤坏死因子拮抗剂诱导治疗期间治疗药物监测的作用：原发性无反应的定义和管理的演变
Inflamm Bowel Dis. 2015 Jan;21(1):182-97. doi: 10.1097/MIB.0000000000000202.
7
Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?在炎症性肠病患者中，在前两种抗TNF药物治疗失败后使用第三种抗TNF药物：这值得吗？
Scand J Gastroenterol. 2015 Apr;50(4):379-86. doi: 10.3109/00365521.2014.928901. Epub 2015 Jan 30.
8
Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease.炎症性肠病患者使用两种前序抗 TNF 单克隆抗体治疗失败后，使用第三种抗 TNF 单克隆抗体的长期疗效。
Aliment Pharmacol Ther. 2012 Sep;36(5):459-66. doi: 10.1111/j.1365-2036.2012.05214.x. Epub 2012 Jul 11.
9
Optimizing anti-TNF treatments in inflammatory bowel disease.优化炎症性肠病的抗 TNF 治疗。
Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19.
10
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).老年炎症性肠病患者与年轻患者相比坚持使用抗肿瘤坏死因子治疗：来自西西里炎症性肠病网络（SN-IBD）的数据。
Drugs Aging. 2020 May;37(5):383-392. doi: 10.1007/s40266-020-00744-3.
引用本文的文献
1
Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD Patients.对HLA基因型在炎症性肠病患者免疫原性及抗TNF治疗继发性难治性中作用的分子洞察
Int J Mol Sci. 2025 Jul 28;26(15):7274. doi: 10.3390/ijms26157274.
2
Psoas muscle CT radiomics-based machine learning models to predict response to infliximab in patients with Crohn's disease.基于腰大肌CT影像组学的机器学习模型预测克罗恩病患者对英夫利昔单抗的反应
Ann Med. 2025 Dec;57(1):2527954. doi: 10.1080/07853890.2025.2527954. Epub 2025 Jul 5.
3
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study.炎症性肠病患者静脉注射或皮下注射英夫利昔单抗的群体药代动力学模型：来自一项前瞻性队列研究的真实世界数据
Gut Liver. 2025 May 15;19(3):376-387. doi: 10.5009/gnl240503. Epub 2025 Apr 21.
4
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.炎症性肠病中生物制剂反应的药物遗传学：一项系统评价
Int J Mol Sci. 2025 Feb 19;26(4):1760. doi: 10.3390/ijms26041760.
5
High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia.高通量全外显子组测序及大规模计算分析以鉴定预测沙特阿拉伯炎症性肠病患者维多珠单抗反应状态的遗传生物标志物。
Biomedicines. 2025 Feb 13;13(2):459. doi: 10.3390/biomedicines13020459.
6
Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.炎症性肠病中预测反应的发病机制与精准医学：进展与未来方向
eGastroenterology. 2024 Jan 18;2(1):e100006. doi: 10.1136/egastro-2023-100006. eCollection 2024 Jan.
7
Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.新型双特异性纳米抗体通过靶向 TNF-α 和 IL-23p19 生物活性减轻实验性肠炎小鼠的炎症反应。
Clin Transl Med. 2024 Mar;14(3):e1636. doi: 10.1002/ctm2.1636.
8
Predictive biomarkers for anti-TNF alpha therapy in IBD patients.炎症性肠病患者抗 TNF-α 治疗的预测生物标志物。
J Transl Med. 2024 Mar 16;22(1):284. doi: 10.1186/s12967-024-05058-1.
9
Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients.巴西炎症性肠病患者对英夫利昔单抗治疗反应的预测因素
Therap Adv Gastroenterol. 2023 Nov 15;16:17562848231210053. doi: 10.1177/17562848231210053. eCollection 2023.
10
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.免疫基因模块在血液中的基础表达与克罗恩病患者对 TNF 拮抗剂治疗的初始应答相关。
J Crohns Colitis. 2024 Mar 1;18(3):431-445. doi: 10.1093/ecco-jcc/jjad166.
本文引用的文献
1
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?优化炎症性肠病的生物治疗：客观指标，但何时、如何以及多久进行一次？
BMC Gastroenterol. 2015 Dec 18;15:178. doi: 10.1186/s12876-015-0408-x.
2
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.优化抗TNF-α治疗：英夫利昔单抗和阿达木单抗的血清水平与炎症性肠病患者的黏膜愈合相关。
Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2. doi: 10.1016/j.cgh.2015.10.025. Epub 2015 Oct 29.
3
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.系统评价：预测和优化克罗恩病抗TNF治疗反应——实用管理算法
Aliment Pharmacol Ther. 2016 Jan;43(1):30-51. doi: 10.1111/apt.13445. Epub 2015 Oct 30.
4
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.炎症性肠病治疗靶点选择（STRIDE）：确定达标治疗的治疗目标
Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25.
5
C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.英夫利昔单抗诱导治疗开始后2周时的C反应蛋白水平可预测溃疡性结肠炎患者的预后：一项3年随访研究。
BMC Gastroenterol. 2015 Aug 14;15:103. doi: 10.1186/s12876-015-0333-z.
6
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.英夫利昔单抗第2周的首次谷浓度可预测溃疡性结肠炎诱导治疗的未来结局——一项多中心前瞻性随机对照试验及其事后分析的结果
J Gastroenterol. 2016 Mar;51(3):241-51. doi: 10.1007/s00535-015-1102-z. Epub 2015 Jul 11.
7
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.伴随免疫调节剂治疗对肿瘤坏死因子治疗克罗恩病疗效和安全性的影响：安慰剂对照试验的荟萃分析。
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2233-40.e1-2; quiz e177-8. doi: 10.1016/j.cgh.2015.06.034. Epub 2015 Jun 30.
8
Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.儿童炎症性肠病中的粪便微生物群及其与炎症的关系。
Am J Gastroenterol. 2015 Jun;110(6):921-30. doi: 10.1038/ajg.2015.149. Epub 2015 May 19.
9
Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.阿什肯纳兹犹太血统可预防抗英夫利昔单抗抗体的形成及治疗失败。
Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673.
10
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.英夫利昔单抗经粪便流失与重度溃疡性结肠炎患者治疗应答不足相关。
Gastroenterology. 2015 Aug;149(2):350-5.e2. doi: 10.1053/j.gastro.2015.04.016. Epub 2015 Apr 25.
Zotero 插件